A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Inclusion Criteria.

- Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor
Receptor 2 Negative (HER2-) breast cancer.

- Recurrent, locally advanced, unresectable or metastatic breast cancer with disease
progression following anti-estrogen therapy.

- Prior treatment with at least 2 chemotherapy regimens:

- At least 1 of these regimens must have been administered in the metastatic
setting.

- At least 1 of these regimens must have contained a taxane.

- No more than 2 prior chemotherapy regimens in the metastatic setting.

- Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group
scale.

- Have discontinued all previous therapies for cancer.

- Have the presence of measureable disease as defined by Response Evaluation Criteria in
Solid Tumors Version 1.1.

Exclusion Criteria:

- Have either a history of central nervous system (CNS) metastasis or evidence of CNS
metastasis on the magnetic resonance image of brain obtained at baseline.

- Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6)
inhibitor.

- Have received treatment with a drug that has not received regulatory approval for any
indication within 14 or 21 days of the initial dose of study drug.

- Have had major surgery within 14 days of the initial dose of study drug.

- Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
in-situ of the cervix).